Navigation Links
Unigene's Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
Date:12/12/2012

oint; the ability to treat osteoporosis with an orally delivered therapeutic; the continued advancement of Unigene's oral PTH program; and Unigene's ability to build a robust portfolio of proprietary partnerships in peptide-based therapeutics based on its Peptelligence™ platform. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These known and unknown risk factors include, but are not limited to: the delay in obtaining or the failure to obtain regulatory approvals for our products and the products of our licensees that may generate royalty and milestone payments to us, our ability to achieve product sales and royalties, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies and our ability to enter into favorable new agreements with such companies, our ability to cut expenses and maintain efficiencies, our ability to enter into new financing arrangements,  the ability of our products to gain market acceptance and increase market share, the uncertainty of results of animal and human testing, the risk of product liability and liability for human clinical trials, our dependence on patents and other proprietary rights and the risks associated with patent litigation, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, general economic and business conditions, our history of losses and ability to achieve profitability, litigation and other risk factors discussed in our Securities and Exchange Commission ("SEC") filings, including our annual report on Form 10-K and our quarterly reports on F
'/>"/>
SOURCE Unigene Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
2. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
3. uniQure Initiates Phase I in Acute Intermittent Porphyria
4. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
5. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
6. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
7. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
8. Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
9. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
10. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
11. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... BERWYN, Pa. , July 25, 2014  AMETEK, ... appointment of Kurtis L. Goos as Vice ... Engineered Materials, Interconnects and Packaging (EMIP) Division. ... has extensive general management and business development experience, especially ... to make important contributions to the continued growth and ...
(Date:7/25/2014)... NORTH CHICAGO, Ill., July 25, 2014 ... PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION ... RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION AbbVie (NYSE: ... quarter ended June 30, 2014. "This was ... and earnings per share above our original guidance and announced ...
(Date:7/24/2014)... , July 24, 2014   AcelRx Pharmaceuticals, Inc. ... focused on the development and commercialization of innovative therapies ... confirmed the PDUFA date for Zalviso remains July 27, ... rumor circulated online stating the Food and Drug Administration ... there has been no notification to the company from ...
Breaking Medicine Technology:AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35
... 5, 2011 meridianEMR, the market leader in EHR ... Somerville, New Jersey was the first meridianEMR customer to ... Centers for Medicare and Medicaid Services (CMS). On July ... $54,000 for three physicians via direct deposit. The group ...
... Biotech Ltd. (Nasdaq: SVA ), a leading ... of Jacob Chik Keung Ho, its Chief Financial Officer, for ... a new Chief Financial Officer to replace Mr. Ho, who ... 2011.  Ms. Nan Wang, Vice President of Sinovac, has been ...
Cached Medicine Technology:meridianEMR® Customers Start Receiving Meaningful Use Incentive Payments 2meridianEMR® Customers Start Receiving Meaningful Use Incentive Payments 3Sinovac Announces Management Changes 2Sinovac Announces Management Changes 3
(Date:7/25/2014)... Garth Brooks Chicago tickets go on sale Friday, ... Garth Brooks was one of the leaders on the country ... 1989. Since "Much Too Young (To Feel This Damn Old)" was ... Okl. native and in the years that he has been away ... stage and in the recording studio. Between 2001 and 2009, fans ...
(Date:7/25/2014)... 25, 2014 -- The Elizabeth Glaser Pediatric AIDS ... the Medicines Patent Pool (MPP) and Gilead Sciences, ... (TAF), a promising new HIV medication. The agreement ... (AIDS 2014) in Melbourne, Australia. , While ... early data suggests it could be a key ...
(Date:7/25/2014)... A report released by the Juvenile Diabetes ... 2013 (July 1, 2012- June 30, 2013). , Outside of ... is the largest single funder of type 1 diabetes research ... with most of the top research centers. There is ... 1 diabetes in the near future. , Since the 2008 ...
(Date:7/25/2014)... Mateo, CA (PRWEB) July 25, 2014 ... an upcoming episode of Innovations with Ed Begley Jr, ... and show times TBA. , For more than four ... the Bay Area community through its residential alcohol and ... will educate on Project Ninety's humble idea and how ...
(Date:7/25/2014)... 2014 Stwd.co.uk, one of the leading ... of cheap evening dress for women. In ... big promotion for these items. They are available at ... last until August 30. , “We are pleased to ... outfits, we have a large number of stylish special ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 2Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 3Health News:Report: JDRF 2013 Annual Research Spending Down by $50 million 2Health News:Project Ninety to be Featured on Innovations with Ed Begley, Jr. 2Health News:Project Ninety to be Featured on Innovations with Ed Begley, Jr. 3Health News:Famous Supplier Stwd.co.uk Announces Its New Selection of Evening Dresses for Women 2
... The number of airline mishaps attributed to pilot error ... analysis conducted by researchers at the Johns Hopkins Bloomberg ... airline mishaps remained stable during that time, the proportion ... rate of mishaps related to a pilots poor decision-making ...
... New Advice for Doctors About Low-Fat, Low-Carb Restricted ... 28 The American,Diabetes Association (ADA) today issued ... providers treat people with diabetes,using the most current ... occurs in the Medical Nutrition Therapy,section dealing with ...
... deprive them of rest needed for healing, study says ... patterns of intensive care unit (ICU) patients are so ... restorative phases of sleep that help promote healing, says ... Southwestern Medical Center at Dallas. , The study ...
... Eclipsys Corporation(R),(Nasdaq: ECLP ), The Outcomes ... 2008 JPMorgan Healthcare Conference taking place from,January 7th ... http://www.newscom.com/cgi-bin/prnh/20050209/FLW006LOGO ), Eclipsys executives will ... 3:00 p.m. Pacific time. To access the live ...
... The National Drug,Intelligence Center (NDIC), a ... nation,s principal center for strategic drug intelligence, ... This strategic,assessment presents an analysis of key ... and abuse in the,United States. The assessment ...
... SAN FRANCISCO, Dec. 27 OneMedPlace will hold its ... the Sir Francis Drake,Hotel in Union Square., This ... cap public,companies and early stage venture backed companies to ... both public and private, will present at,the conference and ...
Cached Medicine News:Health News:Pilot error declines as factor in airline mishaps 2Health News:ADA Issues New Clinical Practice Recommendations 2Health News:ADA Issues New Clinical Practice Recommendations 3Health News:ICU Patients Not Getting Enough Sleep 2Health News:Eclipsys to Present at JPMorgan Healthcare Conference 2Health News:Eclipsys to Present at JPMorgan Healthcare Conference 3Health News:National Drug Intelligence Center Releases 2008 National Methamphetamine Threat Assessment 2Health News:OneMedPlace Emerging Healthcare Technologies Finance Forum Jan 7, 8th 2
... non-adhesive sealing method maintains the ... (HALS) procedures, allowing the surgeon ... throughout. Because HALS requires incisions ... patients experience less trauma compared ...
... series offers a range of standard, ... design delivers therapy to meet the ... results in commercial and clinical effectiveness ... in the SleepStyle 200 series is ...
... The SleepStyle 200 series offers ... integrated CPAP models. The design delivers ... patients. Performance features promote results in ... care. The strongest differentiator in the ...
... series offers a range of standard, ... design delivers therapy to meet the ... results in commercial and clinical effectiveness ... in the SleepStyle 200 series is ...
Medicine Products: